Ton N.M. Schumacher, Ph.D.

The Netherlands Cancer Institute

Ton N.M. Schumacher, Ph.D.

The Netherlands Cancer Institute

Dr. Ton N.M. Schumacher is a co-founder of Neogene Therapeutics. He currently serves as Senior Member at The Netherlands Cancer Institute and Professor of Immunotechnology at Leiden University Medical Center. His research focuses on the development of novel technologies to study and manipulate T cell responses, in particular in the context of cancer and cancer immunotherapy.

Dr. Schumacher is a serial entrepreneur in the immuno-oncology space. Among others, he co-founded AIMM Therapeutics, T Cell Factory (acquired by Kite Pharma, Inc. in 2015) and Neon Therapeutics (IPO in 2018). He is also a Venture Partner at Third Rock Ventures.

Amongst other things, the Schumacher lab has developed technology for high-throughput identification of tumor-specific T cells, has described strategies for TCR gene therapy, and has elucidated the role of cancer neo-antigens in cancer immunotherapy. Dr. Schumacher has authored more than 200 peer-reviewed publications and received numerous awards in recognition for his research, including the Amsterdam Inventor Award, the Queen Wilhelmina Research Award, the San Salvatore Award, the Meyenburg Cancer Research Award, the Peter Speiser Award and the William B. Coley Award.